Matt Darin

Curaleaf Holdings, Inc. (TSX:CURA) (OTCQX:CURLF) has appointed its executive chairman Boris Jordan to become the company’s CEO, effective Friday, Aug. 16, 2024. From his beginnings on Wall Street in the 1980s to building and overseeing one of the largest cannabis companies on the East Coast,...

Curaleaf Holdings, Inc. (TSX:CURA) (OTCQX:CURLF) announced on Thursday that it will open two new medical dispensaries, as well as begin co-located adult-use sales at two existing medical dispensaries in New York. Curaleaf Rochester, located at 532 Chili Ave, Rochester, NY 14611, is opening its...

Cannabis industry heavyweights Curaleaf Holdings, Inc. (OTC: CURLF) and Trulieve Cannabis Corp. (OTC: TCNNF) are set to release their second-quarter 2024 financial results in early August. With both companies showing promising growth and strategic expansions in Q1, investors and industry analysts...

Curaleaf Holdings, Inc. (TSX:CURA) (OTCQX:CURLF) announced on Monday the launch of an all-new line of hemp-derived THC products under its Select and Zero Proof brands. Starting on June 26, products will be available to order directly for consumers in 25 states and the District of Columbia via...

Healthcare data company KindlyMD, Inc. (NASDAQ:KDLY) has teamed up with the U.S. cannabis giant Curaleaf Holdings, Inc. (TSX:CURA)(OTCQX:CURLF) to provide educational resources and information with a community perspective on holistic pain management and treatment. What Happened KindlyMD said its...

Editor’s note: This story has been corrected to reflect that Curaleaf is headquartered in New York City. Curaleaf CEO Matt Darin told Benzinga at the Cannabis Capital Conference in Miami that the company has recently increased its presence in New York. The New York City-based...

Curaleaf Holdings, Inc. (OTC: CURLF), a leading international cannabis company, reported its financial results for the first quarter of 2024. Curaleaf’s CEO, Matt Darin, highlighted the company's focus on expanding its brand globally, leveraging significant market catalysts such as...

At the Benzinga Cannabis Capital Conference in Hollywood, Florida, Constantin von der Groeben, managing director of Demecan, declared a pivotal moment for global cannabis legislation. ‘We’ve reached a tipping point. I think there’s no stepping back from Germany’s cannabis...

Germany recently made headlines by legalizing recreational cannabis in February, joining Malta and Luxembourg as pioneers in the EU. The German parliament’s approval of the CanG bill marks a major shift in the nation’s drug policy, moving away from strict prohibitions. This legislation...

In a bold stance on U.S. cannabis policy, Vice President Kamala Harris is urging the Drug Enforcement Administration (DEA) to accelerate the process of rescheduling marijuana under the Controlled Substances Act. Speaking at a recent White House meeting with individuals who received pardons for...

President Joe Biden’s historic remarks about cannabis reform in Thursday’s State of the Union speech sparked widespread discussion across the industry, which many cannabis companies shared with Benzinga. Ayr Wellness (OTCQX: AYRWF) president & CEO David Goubert “As a...

Curaleaf Holdings, Inc. (OTCQX:CURLF) reported fourth-quarter financial results Wednesday. “I’m pleased to report that the work we’ve done over the past several quarters has paid off," said Curaleaf's executive chairman Boris Jordan. "Curaleaf ended the year strong and is...

Curaleaf International, part of cannabis giant Curaleaf Holdings Inc (OTCQX:CURLF) (TSX:CURA), has expanded in Poland via the acquisition of Can4Med, the country's pharmaceutical wholesaler specializing in cannabinoid medications. This company said on Tuesday the move will enhance patient access to...

Compact Elegance: Pink Stündenglass Kompact Stündenglass introduces the Pink Kompact, a smaller version of its gravity infuser, just in time for Valentine's Day. The Pink Kompact combines the sophisticated design and kinetic motion activation of its predecessor in a more portable...

Schedule I drugs are defined by the DEA as substances with no “currently accepted medical use and a high potential for abuse.” The list includes heroin, LSD, ecstasy, meth, peyote, and, for the past 24 years, cannabis. With Friday’s release of documents related to the...